Non-invasive test for diagnosis of invasive fungal infection saves cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 30, 2020 Category: Drugs & Pharmacology Source Type: news
SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Jans...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news
Ghana: Oral Treatment of Onychomycosis (Tinea Unguium)
[Ghanaian Times] "I have finger nail infection. I am told it is a fungal infection called Tinea. I have used Griseofulvin in the past. Recently I was put on Itraconazole capsulesby my healthcare provider. My healthcare provider asked me take 200mg twice daily for 1 week, repeat the same for another 1 week the second month and do another 1 week for the third month. The dosing is unusual for me. Will it work?". Yes it will work. It is called Pulse therapy. The alternative is to take 200mg daily for 3 months. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 9, 2020 Category: African Health Source Type: news
Caffeine shot delivers wakeup call on antifungal drug resistance
(University of Edinburgh) The management of fungal infections in plants and humans could be transformed by a breakthrough in understanding how fungi develop resistance to drugs. It was previously thought that only mutations in a fungi's DNA would result in antifungal drug resistance. Current diagnostic techniques rely on sequencing all of a fungi's DNA to find such mutations. Scientists from the University of Edinburgh have discovered that fungi can develop drug resistance without changes to their DNA -- their genetic code. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 9, 2020 Category: International Medicine & Public Health Source Type: news
Cochrane review informs guidelines on managing histoplasmosis in people living with HIV
In a newsystematic review, an author team from the Cochrane Infectious Diseases Group explored the evidence regarding managing histoplasmosis in people with HIV. Their review informed the PAHO/WHO guideline development process. The review authors worked with the guideline development group to formulate key questions, including which antifungal drug to start, how long to continue, and when to start antiretroviral medication. They also looked at tuberculosis therapy when people were infected with tuberculosis, HIV, and histoplasmosis.Histoplasmosis is an infection caused by inhaling a fungus called Histoplasma. The mos...
Source: Cochrane News and Events - August 11, 2020 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Bacterial, Fungal Coinfection Uncommon in COVID-19 Patients
FRIDAY, July 31, 2020 -- Bacterial and fungal infections are uncommon in hospitalized COVID-19 patients, but coinfection is associated with high mortality and antibiotic use is widespread, according to a study published in the July issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news
Isavuconazole for the treatment of invasive fungal infection in solid organ transplant recipients: experience from a referral centre
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 1, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news
Current use of baseline chest CT in haematology patients at high risk for invasive fungal infection
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 24, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news
New family of enzymes reveals the Achilles' heel of fungal pathogens
(Canadian Glycomics Network) Aspergillus fumigatus is a fungal species that can cause serious illnesses in immunocompromised individuals. Infections caused by A. fumigatus are difficult to eliminate because the fungus often aggregates into small communities called " biofilms, " which protect the pathogens from antifungal agents and help the fungus evade the immune system. GlycoNet scientists Drs. Lynne Howell and Don Sheppard recently identified a key enzyme in A. fumigatus that could lead to therapeutics to treat these fungal infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 17, 2020 Category: Infectious Diseases Source Type: news
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Olorofim is currently in Phase 2b development for the treatment of life-threatening fungal infections
MANCHESTER, England and VIENNA, Austria, June 10, 2020 -- (Healthcare Sales & Marketing Network) -- F2G Ltd, a UK- and Austria-based biotech developin... Biopharmaceuticals, FDA F2G, orotomides, fungal infection, antifungal, Coccidioidomycosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 10, 2020 Category: Pharmaceuticals Source Type: news
Reprogramming of immune system cures child with often-fatal fungal infection
(University of California - Los Angeles Health Sciences) In the June 11 issue of the New England Journal of Medicine, a team of UCLA physicians and scientists describes the first case of immune modulation being used to cure a severe and often fatal fungal infection. The team 'retuned' a 4-year-old's immune system so that it could fight off disseminated coccidioidomycosis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 10, 2020 Category: Infectious Diseases Source Type: news
Cannabis Smoking May Increase Risk for Fungal Infection
THURSDAY, May 14, 2020 -- The likelihood of having a fungal infection was increased in association with cannabis use in 2016, according to a study published online May 13 in Emerging Infectious Diseases, a publication of the U.S. Centers for Disease... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 14, 2020 Category: Pharmaceuticals Source Type: news
Ronald Reagan ’s Secret Cancer Cure
There’s no faster way to purify your body of viruses, bacteria and fungi — and at the same time ramp up your immune system — than a 125-year-old “cure” banned by the FDA.
I’m talking about ozone therapy — and it’s not just good for cleansing your body.
You see, ozone — a special “energized” kind of oxygen — can help heal almost any condition.
Despite being banned by the FDA back in the 1940s, after more than 60 years of successful use, ozone therapy has saved millions of lives in countries where it has become a commonplace medical treatment.
In countries like Germany, I...
Source: Al Sears, MD Natural Remedies - May 12, 2020 Category: Complementary Medicine Authors: Dr.A.Sears Tags: Health Source Type: news
Bacterial and fungal etiology of sepsis in children in the United States: Reconsidering empiric therapy
Conclusion(s): In this nationally representative administrative database, the most common identified pathogen was S. aureus in previously healthy and chronically ill children. In addition, a high proportion of children with sepsis and select chronic diseases had infections with methicillin-resistant S. aureus, fungal infections, Pseudomonas infections, and C. difficile. Clinicians caring for pediatric patients should consider coverage of these organisms when administering empiric antimicrobials for sepsis. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 6, 2020 Category: Consumer Health News Source Type: news
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
